QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Mr. John  Gilardi

Vice President of Corporate Communications & Investor Relations

Mr. Jean-Pascal  Viola

Senior Vice President & Head of Molecular Diagnostics Business Area

Dr. Jonathan G. Sheldon Ph.D.

Senior Vice President of Qiagen Digital Insights Business Area

Mr. Thierry  Bernard

Chief Executive Officer, MD & Member of Management Board

Ms. Stephany  Foster

Senior Vice President & Head of Human Resources

Dr. Roland  Sackers

Chief Financial Officer, MD & Member of Management Board

Dr. Thomas  Schweins

Senior Vice President of Life Science Business Area

Dr. Thomas  Theuringer

Senior Director & Head of External Communications

Mr. Antonio  Santos

Senior Vice President & Head of Global Operations

Pavadinimas	Rinkos kapitalizacija
China Health Group Inc.	0M
Revvity, Inc.	0M
Standard BioTools Inc.	0M
IDEXX Laboratories, Inc.	0M
China Biotech Services Holdings Limited	0M
Sonic Healthcare Limited	0M
Quest Diagnostics Incorporated	0M
Amoy Diagnostics Co., Ltd.	0M
WuXi AppTec Co., Ltd.	0M
Genetic Technologies Limited	0M

Qiagen N.V.

Qiagen N.V. Konkurentų sąrašas

Pagrindiniai konkurentai